Obeticholic Acid/Ezetimibe

奥贝胆酸/依折麦布

Report date: 2021/12/16 10:02:35

Base Information

Drug NameObeticholic Acid/Ezetimibe
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBile acid receptor FXR agonistsNiemann-Pick C1-like protein 1 inhibitorsCholesterol absorption inhibitors
TargetsBile acid receptor FXRNiemann-Pick C1-like protein 1
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Obeticholic AcidEzetimibe
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWaterstone Pharmaceuticals (Wuhan) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWaterstone Pharmaceuticals (Wuhan) Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A